Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage

Clinical Neuropharmacology

Volumn 20, Issue 1, 1997, Pages 67-76

  Gimenez Roldan S ^a,f   Tolosa, E ^c   Burguera, J A ^e   Chacon J ^f   Liano H ^b   Forcadell, F ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c Instituto Grifols   (Spain)

^d AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^e Sandoz Pharma S A E   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Bromocriptine; Combined therapy; Dyskinesias; Fluctuations; Levodopa; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DYSKINESIA; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0343907188     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199702000-00008     Document Type: Article

References (34)

1. Marsden CD, Parkes JD, Quinn N. Fluctuaions in disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S. eds. Movement disorders. New York : Butterworth scientific, 1982:96-122.
2. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-8.
3. Nutt JG, Gaucher ST, Woodward WR. Does an inhibitor, action of levopoda contribute to motor fluctuations ? Neurology 1988;38:1553-7.
4. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;:35:1196-8.
5. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of ParKinson's disease. Neurology 1987;37:826-8
6. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Movement Discord 1989;4:586-94.
7. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levopoda in Parkinson's disease. Movement Disord 1993;3:257-63.
8. Weiner WJ, Factor SA, Sánchez-Ramos JR, et al. Early combination therapy (bromocriptine and levopoda) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-6.
9. Geminiani G, Cesana BM, Tamma F, et al. Interobserver reliability between neurologists in training of Parkinson's disease rating scales. Movement Disord 1991;6:330-5.
10. Hoehn MM, Yahr MD. Parkinsonism: onset progression, and mortality. Neurology 1967;17:427-42.
11. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6.
12. Giladi N, McMohan D, Prtzeborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992;42:333-9.
13. Tolosa E, Forcadell F. Escala de evaluación unificada para la enfemedad de Parkinson : versión española , Barcelone: Sandoz S.A.E., 1987.
14. Fahn S, Elton RL. members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S. Marsden CD, Calne DB, Goldstein M. eds. Recent developments in Parkinson's disease, vol 2. Florham Park: Macmillan Healthcare Information, 1987:153-63, 293-304.
15. England AC, Schwab RS. Postoperative evaluation of selected patients with Parkinson's;disease. J Am Geriatr Soc 1956;4:1219-32.
16. Backheit AMO, Henderson LM, Moore AP, Simpson JA, Thomas M. Long-term doubled masked trial of early treatment with L-Dopa plus bromocriptine versus L -Dopa alone in Parkinson's disease. Eur Neurol 1990;30:108-11.
17. Olson JE. European Multicentre Trial Group, Bromocriptine and levopoda in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Parkinson's disease, anatomy, pathology, and therapy. New York: Raven Press, 1990:421- 3.(Advances in neurology: vol 53).
18. Nakanishi T, Iwata M, Goto I, et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1992;32(suppl 1):9-22.
19. Fisher PA, Przuntek H. Majer M, Welzel D. Combined treatment of early stage of Parkinson's syndome with bromocriptine and levopoda. A multi-center evaluation. Disch Med Wochenschr 1984;109:1279-83.
20. Rinne UK. Early combination of bromocriptine and levopoda in the treatment of Parkinson's disease. In: Fahn S, Marsden CD, Jenner P, Teychenne P, eds. Approaches to the use of bromocriptine in Parkinson's disease. New York: Raven Health Care Communications, 1985:67-14.
21. Kartzinel R, Calne DB. Studies with bromocriptine. Part I. "On-of" phenomena. Neurology 1976;26:508-10.
22. Calne DB, Williams AC, Neophytides A, Plotkin C, Nutt JG, Teychenne PF. Long-term treatment of parkinsonisin with bromoctriptine. Lancet 1978;1:735-8.
23. Caraceni T, Giovannini P, Girotti F, Parati E, Pederzoli M, Scigliano G. Long-term evaluation of combined treatment of Parkinson's disease with L-Dopa, peripheral decarboxylase inhibitors and bromocriptine. Ital J Neurol Sci 1981;2:237-42.
24. Chacon JR, Piqueras L, Pery JM. Bromocriptina en la entfermedad de Parkinson. Experiencia personal. Arch Neurobiol 1982;45:371-80.
25. Lees AJ, Haddad S, Shaw KM, Kohout LJ, Stern GM. Bromocriptine in parkinsonism. A long-term study. Arch Neurol 1978;35:503-5.
26. Olanow CW. A rationale for dopamine agonists as primary therapv for Parkinson's disease. Can J Neurol Sci 1992;19:108-12.
27. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology (Cleveland) 1984;34:991-6.
28. Helly MA, Morris JGL, Reid WGJ, et al. The Sydney Multicentre Study of Parkinson's Disease: a randomised, prospective five year study comparing low-dose bromocriptine with low-dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-10.
29. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
30. Masden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81.
31. Murata M, Kanazawa I. Repeated L-Dopa administration reduces the ability of dopamine storage and abolishes the supersensivity of dopamine receptors in the striatum of intact rats. Neurosci Res 1993;16: 15-23.
32. Giménez-Roldán S, Mateo D. Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations. Clin Neuropharmacol 1994;17:435-44.
33. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-44.
34. Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Le test a la L-Dopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985;141:413-5.